Business ❯ Finance ❯ Market Capitalization ❯ Stock Performance

Investor Relations

Agenus Secures $85M Now and Up to $340M Total to Back a Registrational Colon Cancer Trial

The financing eases immediate cash pressure and shifts the company’s focus to a Phase 3 neoadjuvant study whose longer runway depends on warrant holders providing further capital.

55 ARTICLES

2mo ago

NextEra to Buy Dominion for $67 Billion in Stock, Creating Largest Regulated Utility

3 ARTICLES

2mo ago

Kioxia Sees ¥1.3 Trillion Quarterly Profit, Plans U.S. ADS Listing After AI-Driven Surge

10 ARTICLES

2mo ago

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial

Investor Relations

Agenus Secures $85M Now and Up to $340M Total to Back a Registrational Colon Cancer Trial

NextEra to Buy Dominion for $67 Billion in Stock, Creating Largest Regulated Utility

Kioxia Sees ¥1.3 Trillion Quarterly Profit, Plans U.S. ADS Listing After AI-Driven Surge

Peltz’s Trian Seeks Backers for Potential Wendy’s Take-Private

United CEO Floated Merger With American in White House Meeting, Reports Say

Third Point Launches Proxy Fight at CoStar as Company Defends Homes.com

Nvidia Strikes $20 Billion Groq Deal as AI Demand Keeps Outrunning Supply

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial